Last reviewed · How we verify
Adjuvant FL
Adjuvant FL is a fluorouracil and leucovorin combination chemotherapy regimen designed to enhance immune response and reduce recurrence in cancer patients.
Adjuvant FL is a fluorouracil and leucovorin combination chemotherapy regimen designed to enhance immune response and reduce recurrence in cancer patients. Used for Adjuvant treatment of colorectal cancer, Adjuvant treatment of gastric or gastroesophageal cancer (investigational).
At a glance
| Generic name | Adjuvant FL |
|---|---|
| Also known as | fluorouracil, leucovorin |
| Sponsor | Asan Medical Center |
| Drug class | Antimetabolite chemotherapy combination |
| Target | Thymidylate synthase (via fluorouracil) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
FL (fluorouracil/leucovorin) is a classic adjuvant chemotherapy combination where fluorouracil acts as an antimetabolite to inhibit DNA synthesis, and leucovorin (folinic acid) enhances its cytotoxic effects by stabilizing the fluorouracil-thymidylate synthase complex. When used as an adjuvant therapy, it aims to eliminate residual micrometastatic disease and potentially prime anti-tumor immune responses.
Approved indications
- Adjuvant treatment of colorectal cancer
- Adjuvant treatment of gastric or gastroesophageal cancer (investigational)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Mucositis
- Diarrhea
- Nausea and vomiting
- Hand-foot syndrome
Key clinical trials
- RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) (PHASE1)
- A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) (PHASE1)
- Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II) (EARLY_PHASE1)
- Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer (PHASE2)
- Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision (PHASE2)
- Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adjuvant FL CI brief — competitive landscape report
- Adjuvant FL updates RSS · CI watch RSS
- Asan Medical Center portfolio CI